natgillin/translations-raw huggingface dataset:
Clause 22. A compound comprising a modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of the sequence recited in SEQ ID NO: 549, wherein the modified oligonucleotide comprises 
Spoj koji obuhvaća modificiran oligonukleotid koji se sastoji od 16 vezanih nukleozida koji imaju nukleobaznu sekvencu koja obuhvaća sekvencu koja je navedena u SEQ ID NO: 549, pri čemu modificiran oligonukleotid obuhvaća: segment razmaka koji se sastoji od deset vezanih deoksinukleozida;
The extracts were dried (Na2C03), filtered and evaporated to dryness. 
Ekstrakti se suše (NaxCO;), filtriraju i ispare do suhog.
at least one kite adapted to be driven from ground immersed in at least one wind current; and 
- najmanje jednog zmaja (2) koji je prilagođen na način da se uzgoni sa zemlje uronjen u najmanje jednu struju vjetra (W);
The method according to claim 23, wherein the ammonium salt is ammonium sulfate. 
Metoda prema zahtjevu 20, gdje je amonijeva sol amonijev sulfat.
the base is mixed in a solvent system, wherein the solvent system comprises a straight or branched chain aliphatic alcohol with 1 to 5 carbon atoms; and/or 
Postupak prema zahtjevu 13, gdje sustav otapala sadrži alifatski alkohol ravnog ili razgranatog lanca s 1 do 5 atoma ugljika.
Examples of polyoxyethylene sorbitan fatty acid esters include polyoxyethylene sorbitan monooleate (Tween 80), polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monopalmitate or a combination thereof. 
- pri čemu polioksietilen sorbitan ester masne kiseline sadrži polioksietilen sorbitan monooleat, polioksietilen sorbitan monostearat ili polioksietilen sorbitan monopalmitat ili njihovu kombinaciju.
The system of claim 10, wherein the formulation is for treatment of adult acne, and the formulation further comprises salicylic acid. The system of claim 10, wherein the formulation is for treatment of cellulite, and the formulation further comprises adipogenesis inhibitors, lipogenesis inhibitors, and/or or lipolytic agents. 
Upotreba prema zahtjevu 12, naznačena time što se formulacija koristi: a) = kao podloga za šminku, pri čemu formulacija nadalje sadrži jednu ili više odgovarajućih boja; b) za povećanje vlažnosti kože i/ili ublažavanje finih linija ili bora; ili c) - zatretiranje celulita, pri čemu formulacija nadalje sadrži inhibitore adipogeneze, inhibitore lipogeneze i/ili lipolitička sredstva.
containing sodium dihydrogen phosphate and disodium hydrogen phosphate). 
koji sadrži natrijev dihidrogen fosfat i dinatrijev hidrogen fosfat).
The 3D viewing glasses according to Claim 1, wherein the dielectric coating is non-uniform. 
Naočale za 3D gledanje prema zahtjevu 3, naznačene time što zakrivljena površina ima polumjer od približno 40 mm-200 mm.
Preferably the amount of ulipristal acetate or a metabolite thereof is effective to alleviate the symptoms of uterine leiomyomata without clinically significant antiglucocorticoid activity. In a particular embodiment, the patient may be administered with an oral dosage of ulipristal acetate during a period of about 2 to about 4 months. 
Ulipristal acetat, 1li bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB4183 za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 pri čemu se primjenjuje u obliku oralne doze kroz period od oko 2 do oko 4 mjeseca.
and n+1 second winches which are respectively connected to the n+1 second lines and adapted to wind and unwind independently each of the n+1 second lines. 
i n+1 drugih vitla (13) koja su odgovarajuće spojena na n+1 drugih konopaca (14) i prilagođena su za namatanje i odmatanje neovisno svakog od n+1 drugih konopaca.
culturing a population of human DE cells on a support coated with a human laminin in a hepatic induction medium to produce a population of human hepatoblast-like cells, and culturing said population of human hepatoblast-like cells on a support coated with a human laminin in a hepatic maturation medium to produce a population of human fetal hepatocyte-like cells. 
(i) uzgoj populacije ljudskih DE stanica na podlozi koja je obložena ljudskim lamininom u jetrenom indukcijskom mediju kako bi se proizvela populacija ljudskih hepatoblastno-sličnih stanica, i (ii) uzgoj navedene populacije ljudskih hepatoblastno-sličnih stanica na podlozi koja je obložena s ljudskim lamininom u mediju za sazrijevanje jetre kako bi se proizvela populacija ljudskih fetalnih hepatocitno-sličnih stanica.
The composition of claim 1 as carrier, modifier or protector of living cells, biological and pharmacological materials and substances. 
Sastav prema bilo kojem od zahtjeva 1 do 21, kao nosač, modifikator ili zaštitnik živih stanica, bioloških 1 farmakoloških materijala 1 tvari.
The filter aid was washed with 30 L of ethanol of 60 °C. At 60 °C, a solution of 13.5 kg of maleic acid in 90 L of ethanol was added to the combined filtrates and stirring was continued for 30 minutes. 
Pomoćni filtar je ispran s 30 L etanola zagrijanog na 60 *C. Na 60 "C, dodana je otopina 13,5 kg maleinske kiseline u 90 L etanola u sjedinjene filtrate te je miješanje nastavljeno tijekom 30 minuta.
The composition for use according to claim 1 packaged together with instructions for using the composition to treat a cardiovascular disorder. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se pakira zajedno s uputama za upotrebi pripravak za liječenje kardiovaskularnog poremećaja.
A dispensing assembly according to any preceding claim comprising a housing for enclosing the container, preferably the housing supports the container. 
Raspršivač sukladno bilo kojem prethodnom zahtjevu koji sadrži kućište (2) za zatvaranje spremnika.
The method according to claim 1, characterized in that said filler material (3) is constituted by concrete. 
Postupak prema zahtjevu 1, naznačen time, da je spomenuti materijal punila (3) sastavljen od betona,
The solids were washed with 1,2-dichloroethane and dried in vacuo. 
Krutine se isperu sa 1,2-diklorostanom i osuše u vakuumu.
Furthermore, basic formulations of the present invention supplemented with probiotic bacterial strains belonging to for instance either the Bifidobacterium or Lactobacillus genus, provides both the probiotic strains and a selective energy source, resulting in a so-called synbiotic effect. 
Nadalje, osnovne formulacije koje su predmetom ovog izuma, obogaćene probiotičkim sojevima bakterija, npr. iz Todova Bifidobacterium i Lactobacillus, osiguravaju i probiotičke sojeve i selektivan izvor energije, čime se postiže tzv. sinobiotički učinak.
The electrolyte may further contain modification agents improving accumulator functions at high temperatures and/or removing decomposition products and/or protecting the accumulator from overcharging and/or substances controlling the size of metal lithium dendrites. 
Litijski akumulator prema zahtjevu 1, u kojem elektrolit nadalje sadrži sredstva za modifikaciju, poboljšavajući akumulator od prekomjernog punjenja i/ili tvari koje djeluju na veličinu dendrita metala litija.
or a pharmaceutically acceptable salt or hydrate thereof; wherein the virus is selected from the group consisting of viruses of the orthomyxoviridae, paramyxoviridae, arenaviridae, bunyaviridae, flaviviridae, filoviridae, togaviridae, picornaviridae, and coronaviridae families. 
Spoj za primjenu prema zahtjevu 5, naznačen time da je druga virusna RNK polimeraza izabrana iz grupe koja se sastoji od virusnih polimeraza orthmyxoviridae, paramyxoviridae, arenaviridae, bunyaviridae, flaviviridae, filoviridae, togaviridae, picornaviridae, i coronaviridae.
A protein which is encoded by a nucleic acid sequence according to SEQ ID NO: 6. 
Protein, naznačen time što ga kodira nukleinskokiselinski slijed u skladu sa SEQ ID NO: 6.
removing R1 from the compound of the Formula VI in situ in the presence of the solvent used in steps (g) and (h) to form the compound of the Formula IX or a salt thereof; and whereafter the compound of the Formula IX obtained in the form of the free base may be converted into a salt form and the compound of the Formula IX obtained in the form of a salt may be converted into the free base or into the form of an alternative salt, if necessary. 
VIN; i (h) reakciju spoja sa formulom VIII sa 4-bromo-2-fluoroanilinom in situ u prisutnosti otapala koje se koristi u koraku (g) sa svrhom dobivanja klorovodikove soli spoja sa formulom VI; i gdje spoj sa formulom VI, dobiven u obliku klorovodikove soli, može se konvertirati u slobodnu bazu ili u oblik neke alternativne soli, ako je potrebno.
The reaction mixture is stirred at 0 °C for 30 minutes, at room temperature for 3 hours and then poured into water (400 ml). 
Reakcijsku smjesu se miješa 30 minuta pri O"C, 3 sata pri sobnoj temperaturi i zatim se prelije u vodu (400 ml).
The results are shown in Table 1 below. 
Rezultati su prikazani u niže danoj Tablici 1.
The formulation of claim 3, wherein the at least one hydrotrope is chosen from a salt of xylene sulphonic acid, a salt of cumene sulphonic acid, and a salt of toluene sulphonic acid. 
Formulacija prema zahtjevu 4, naznačena time da je barem jedan hidrotrop odabran od soli ksilen sulfonske kiseline, soli kumen sulfonske kiseline i soli toluen sulfonske kiseline.
A method of treating diabetes comprising: providing a therapeutic composition to a pancreas in vivo comprising (i) glucokinase expression cassette configured to express a functional glucokinase protein in a pancreatic cell, (ii) a tyrosine phosphatase 1B inhibitor, and (iii) a Pdx-1 expression cassette configured to express a functional Pdx-1 protein in a pancreatic cell, wherein pancreatic beta cells are induced in the pancreas and provide insulin to treat diabetes. The method of claim 22, wherein diabetes is type 1 diabetes. The method of claim 22, wherein diabetes is type 2 diabetes. 
Kombinacija za uporabu prema zahtjevu 1, naznačena time da je za uporabu za liječenje dijabetesa tipa 1 ili tipa 2, te kombinacija sadrži: (1) kasetu za ekspresiju glukokinaze koja je konfigurirana da eksprimira funkcionalni protein glukokinaze u stanici gušterače, (ii) inhibitor tirozin fosfataze 1B koji je shRNA inhibitor proteina tirozin fosfataze 1B (PTPIB) ili PTPIB antisensna DNA i (iii) Pdx-1 ekspresijska kaseta je konfigurirana da eksprimira funkcionalni protein Pdx-1 u stanici gušterače, te je kombinacija prilagođena da inducira beta stanice gušterače u gušterači.
A composition comprising the bacterium deposited under accession number NCIMB 42380 or a bacterium that has a 16s rRNA sequence that is at least 98% identical to SEQ ID NO:1, for use in a method of treating or preventing neutrophilic asthma. 
PATENTNI ZAHTJEVI Sastav koji obuhvaća održivu bakteriju koja je deponirana pod pristupnim brojem NCIMB 42380 ili održivu bakteriju koja ima 16s rRNK sekvencu koja je najmanje 98% identična sa SEQ ID NO:1, za upotrebu u postupku liječenja ili prevencije raka.
∘ four telescopic crossbeams (14, 14', 14", 14"') spanning from the prow to stern, starboard longitudinal beam, to the prow to stern, port longitudinal beam, 
četiri teleskopske poprečne grede (14, 14’, 14", 14"’) koje se protežu od pramca do krme, longitudinalna greda desne strane broda, od pramca do krme, longitudinalna greda porta
is D-arginine or a non-cationic amino acid, where X4 is not glycine, proline or an amino acid with an acidic side chain; 
je D-arginin ili ne-kationska aminokiselina, gdje X4 nije glicin, prolin ili aminokiselina s bočnim kiselinskim lancem;
The method according to claim 1, wherein the composition further comprises at least one of phloxine B, rose bengal, eosin B, fluorescein, erythrosine B, saffranin O, basic fuchsin, acid fuschin, 3,3′ dihexylocarbocyanine iodide, carminic acid, indocyanine green, crocetin, a-crocin (8,8-diapo-8,8-carotenoic acid), zeaxanthine, lycopene, a-carotene, B-carotene, merbromine, bixin, fucoxanthine, methyl violet, neutral red, para red, amaranth, carmoisine, allura red AC, tartrazine, orange G, ponceau 4R, methyl red, murexide-ammonium purpurate, pyronine Y, and pyronine B. The method according to claim 1, wherein the composition further comprises a healing factor selected from hyaluronic acid, glucosamine, and allantoin. 
Kompozicija za primjenu prema bilo kojem od patentnih zahtjeva 1 do 4, gdje fotoaktivator dalje sadrži floksin B, eozin B, bengal roze, fluorescein, eritrozin B, rodamin B, rodamin G, rodamin WT, smjesu praha crvenog šafrana, anato ekstrakt, i ekstrakt smeđe alge, šafranin O, bazni fuksin, kiseli fuksin, 3,3'-diheksilokarbocijanin jodid, karminsku kiselinu, indocijanin zelenu, krocetin, a-krocin (8,8-diapo-8,8-karotenska kiselina), zeaksantin, likopen, a-karoten, B-karoten, biksin, fukoksantin, metil ljubičastu, neutralno crvenu, krv crvenu, amarant, karmoizin, alura crvenu AC, tartrazin, narančastu G, ponso 4R, metil crvenu, mureksid-amonij purpurat, pironin Y i pironin B.
According to a further embodiment, the beverage container is adapted to expose the beverage to an external isostatic pressure exceeding the equilibrium pressure of the beverage by at least 1.2 bar, preferably 1.2-60 bar, more preferably 1.5-10 bar, most preferably about 2 bar. 
Kontejner za napitak u skladu sa patentnim zahtjevom 5, gdje je kontejner za napitke adaptiran da izloži navedeni napitak vanjskom izostatičkom pritisku koji prelazi navedeni ravnotežni pritisak navedenog napitka za najmanje 1.2 bara, poželjno 1.2 - 60 bara, još poželjnije 1.5 - 10 bara, najpoželjnije oko 2 bara.
and R2 are each independently selected from alkoxy, alkyl, and halo; and when s is 2, 3, or 4, each R5 on the ring is independently selected from alkoxy, alkyl, and aryl, wherein the alkyl can optionally form a fused three- to six-membered ring with an adjacent carbon atom, wherein the three- to six-membered ring is optionally substituted with one or two alkyl groups; provided that the two heterocyclic rings substituting the imidazole rings are identical; the process comprising: 
R! i R* su svaki nezavisno izabrani između alkoksi, alkil, i halogen; i kada s je 2, 3,1li 4, svaki R* na prstenu je nezavisno izabran između alkoksi, alkil, 1 aril, gdje alkil po izboru može formirati fuzionirani tri- do šesteročlani prsten sa susjednim atomom ugljika, gdje je tri- do šesteročlani prsten po izboru supstituiran s jednom ili dvije alkilne skupine; uz uvjet da su dva heterociklička prstena koja supstituiraju imidazolske prstene identični; postupak obuhvaća:
A compound of claim 1 wherein the compound has the formula: wherein the subscript p is an integer from 0 to 3. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da spoj ima formulu:
4-Methyl-5-(4-pyridazinyl)-2,4-dihydro-3 H -1,2,4-triazole-3-thione, as intermediate in the preparation of the compound of formula (I) according to claim 5. 
o i osu \ 1 naznačen time što je međuprodukt u dobivanju spoja formule (1) u skladu s patentnim zahtjevom 7.
A motor (1) as claimed in claim 19, wherein the body (2) is made from a material having a high modulus of elasticity. 
Motor (1) prema bilo kojem od Zahtjeva 20 do 41, naznačen time, da je tijelo (2) napravljeno od materijala sa visokim modulom elastičnosti.
A solid form of a hydrochloride salt of 3-(5-amino-2-methyl-4-oxo-4 H -quinazolin-3-yl)-piperidine-2,6-dione: having an X-ray powder diffraction pattern comprising peaks at about 8.6, 13.1, 20.5 and 26.3 degrees 2θ. 
[image], naznačen time što ima uzorak difrakcije rendgenskih zraka na prahu s maksimumima na otprilike 8,6, 13,1, 20,5 i 26,3 °2θ.
The compound of claim 11, wherein the skeletal muscular disorders and diseases are selected from the group consisting of skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. 
Spoj prema patentnom zahtjevu 11, naznačen time što su poremećaji i bolesti skeletnih mišića izabrani iz grupe koju čine zamor skeletnog mišića, zamor skeletnog mišića izazvan pojačanom fizičkom aktivnošću, mišićna distrofija, poremećaji bešike 1 inkontinencija.
The process as claimed in claim 1 or 2 wherein step (i) is carried out in the presence of a palladium catalyst selected from the group consisting of tetrakis(triphenylphosphine)palladium, palladium on activated charcoal, and palladium on alumina. 
Postupak kako je prijavljen u patentnim zahtjevima 1 do 3, naznačen time da se korak (1) provodi u prisutnosti paladija kao katalizatora odabranog od sljedećih: tetrakis(trifenilfosfin)paladj, paladij na aktivnom ugljenu ili paladij na aluminijevom oksidu.
The method of claim 16, after the initial portion of the start-up mode, increasing over time the flow of dewatered sludge through the heat exchanger and decreasing the flow of dewatered sludge through the heat exchanger bypass line during the startup mode. 
Postupak prema patentnom zahtjevu 12, naznačeno time da se dalje nakon početne faze pokretanja postupka, povećava tijekom vremena protok odvodnjenog mulja kroz izmjenjivač topline (216) i smanjuje protok odvodnjenog mulja kroz obilazni vod (25) izmjenjivača topline tijekom pokretanja postupka.
Example: Zirconia particles are dispersed in a resin base. 
Primjer: čestice cirkonijeva oksida su dispergirane u bazi za smolu.
A process for making the vaccine according to claim 14 which comprises the step of mixing the immunogenic composition of any of claims 1 to 13 with a pharmaceutically acceptable excipient. The immunogenic composition of claims 1-13 or the vaccine of claim 14 for use in the treatment of prevention of disease caused by Streptococcus pneumoniae infection. 
Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, gdje pripravak sadrži saharid iz kapsule serotipa 18C konjugiran s TT, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju bolesti uzrokovanih infekcijom sojevima serotipa 19A bakterije Streptococcus pneumoniae.
The polypeptide of claim 7, wherein the polypeptide exhibits a fibrinolytic activity that is inhibited by a-antiplasmin at a rate of inhibition that is at least about 5-fold faster than the rate of inhibition of the fibrinolytic activity of mini-plasmin by a2-antiplasmin. 
Polipeptid prema zahtjevu 8, naznačen time da polipeptid pokazuje fibrinolitičku aktivnost koja je inhibirana s a2-antiplazminom pri stupnju inhibicije koji je najmanje oko 5 puta brži nego što je stupanj inhibicije fibrinolitičke aktivnosti mini-plazmina sa a2-antiplazminom.
removing any protecting group(s); and/or 
uklanjanja jedine ili svih zaštitnih skupina; i/ili
De-activation means (11, 12, 13, 14) configured to de-activate the reception of the said images in correspondence of the overcoming of the said sentinel apparatus of a pre-established minimum de-activation distance; 
- de-aktivacijska sredstva (11, 12, 13, 14) konfigurirana da de-aktiviraju prijem navedenih slika u skladu s prolaskom navedenog nadzornog uređaja unaprijed određene najmanje de-aktivacijske udaljenosti;
the treatment of latent tuberculosis; 
(b) liječenje latentne tuberkuloze;
The method of claim 6, wherein the tumor disease is selected from the group consisting of astrocytoma, oligodendroglioma, meningioma, neurofibroma, glioblastoma, ependymoma, Schwannoma, neurofibrosarcoma, medulloblastoma, melanoma, pancreatic cancer, prostate carcinoma, head and neck cancer, breast cancer, lung cancer, ovarian cancer, endometrial cancer, renal cancer, neuroblastomas, squamous carcinomas, hepatoma, colon cancer and mesothelioma and epidermoid carcinoma. The method of claim 6, wherein the tumor disease bears the tumor cells from an epithelial tumor or the tumor disease is an epithelial tumor. 
Vežuća molekula koja se može vezati na L1, namijenjena upotrebi u skladu s bilo kojim od patentnih zahtjeva 4 do 11, naznačena time što tumorske stanice ili tumorogena bolest su tipa koji se bira iz skupine koju čine astrocitom, oligodendrogliom, meningiom, neurofibrom, glioblastom, ependimom, Schwannom, neurofibrosarkom, meduloblastom, melanom, rak gušterače, karcinom prostate, rak glave i vrata, rak dojke, rak pluća, rak jajnika, rak endometrija, rak bubrega, neuroblastomi, karcinomi pločastih stanica, hepatom, rak debelog crijeva i mezoteliom i epidermoidni karcinom, ili, što su tumorske stanice iz tumora epitela ili što je tumorogena bolest tumor epitela.
A method of preparing a composition according to claim 37, the method comprising admixing said inhibitor of dipeptidyl peptidase IV (DPP-IV), said compound, and said pharmaceutically acceptable carrier. 
Postupak izrade pripravka u skladu sa zahtjevom 37, naznačen time, da postupak obuhvaća miješanje navedenog inhibitora dipeptidil peptidaze IV (DPP-IV), navedenog spoja i navedene farmaceutski prihvatljive podloge.
The system of any one of the preceding claims, wherein said presenting appliance communication further contains an alias associated to said presenter identifier and affiliated to said entry (103) pertaining to said at least one set of connected controlled credentials, and wherein said search for said target record further utilizes said alias contained in said presenting appliance communication (105) to search for said target record comprising said alias in addition to comprising said presenter identifier (108a) and said secret keycode. 
Sustav u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što pošiljka iz navedene naprave za prikazivanje dodatno sadrži pseudonim povezan s navedenim identifikatorom prikazivača i povezan s navedenim unosom (103), koji pripada navedenom najmanje jednom kompletu povezanih kontroliranih vjerodajnica, te gdje navedena potraga za navedenom ciljanom bilješkom dodatno uključuje navedeni pseudonim sadržan u pošiljci iz navedene naprave za prikazivanje (105), gdje potraga za navedenom ciljanom bilješkom uključuje navedeni pseudonim, te uključuje navedeni identifikator prikazivača (108) i navedeni tajni kodni ključ.
reacting Compound 101 with urea or KOCN to produce Compound 102 
reakcije Spoja 101 s ureom ili KOCN kako bi se dobilo Spoj 102;
In some further embodiments of the above objects, the fibrotic condition is selected from a group consisting of liver fibrosis and the inflammatory conditions which predispose to it i.e. acute and chronic hepatitis, biliary disease and toxic liver injury, pulmonary fibrosis, renal fibrosis, including that resulting from diabetic nephropathy, myelofibrosis, pancreatic fibrosis, scleroderma, connective tissue diseases, scarring, skin fibrosis, cardiac fibrosis, organ transplant, vascular stenosis, restenosis, arterial fibrosis, arthrofibrosis, breast fibrosis, muscle fibrosis, retroperitoneal fibrosis, thyroid fibrosis, lymph node fibrosis, bladder fibrosis, pleural fibrosis and COPD, a disease in which airway walls are fibrotic with the accumulation of myofibroblasts and collagen, and like all fibrotic tissues, are contracted. 
Inhibitor VAP-1, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time što je namijenjen upotrebi u liječenju fibrotičnog stanja koje se bira iz skupine koju čine fibroza pluća, fibroza bubrega, uključujući onu koja je posljedica dijabetične nefropatije, mijelofibroza, fibroza gušterače, skleroderma, bolesti vezivnog tkiva, ožiljci, fibroza kože, fibroza srca, presađivanje organa, stenoza krvnih žila, restenoza, arterijska fibroza, artrofibroza, fibroza dojke, fibroza mišića, retroperitonealna fibroza, fibroza štitnjače, fibroza limfnih čvorova, fibroza mokraćnog mjehura, fibroza pleure i COPD, bolest kod koje su dišni putevi fibrotični zbog nakupljanja miofibroblasta i kolagena, te su, i kao 1 sva fibrotična tkiva, kontrahirani.
Carbonate buffers are not preferred as they tend to decompose at high temperatures, causing bubbles to form in the matrix. 
Karbonatni puferi nisu poželjni jer imaju tendenciju da se razgrade na visokim temperaturama, izazivajući formiranje mjehurića u matriksu.
removing the bottle from the pack without completely removing the pack from the case. 
uklanjanja bočice (12) iz pakiranja (14) bez potpunog uklanjanja pakiranja (14) iz kutije (52).